VIP (Vasoactive Intestinal Peptide) is a 28-amino acid neuropeptide that functions as both a neurotransmitter and neuromodulator. Originally discovered in intestinal extracts, VIP is now known to be widely distributed throughout the central and peripheral nervous systems, as well as immune tissues. VIP produces potent vasodilation, regulates smooth muscle activity, modulates immune responses, and influences circadian rhythms. The peptide has significant anti-inflammatory properties and promotes tolerance of self-antigens. VIP is being researched for conditions including inflammatory bowel disease, rheumatoid arthritis, sepsis, and neurodegenerative diseases. Aviptadil (synthetic VIP) is in clinical development for ARDS/COVID-19.
| Research Status | Preclinical |
|---|---|
| Half-Life | ~2 minutes |
| Administration | Intranasal or subcutaneous |
| Typical Dosage | 50-100 mcg intranasal |
| Molecular Weight | 3,326 Da |
| Molecular Formula | C147H237N43O43S |
Activates VPAC1 and VPAC2 receptors throughout the body for multiple physiological effects.
All information is presented for Research Use Only (RUO). Not medical advice.